These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 8931935

  • 21. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T, Lin S, Ji M, Xue N, Liu Y, Zhang Z, Zhang K, Zhang J, Zhang Y, Wang Q, Sheng L, Li Y, Lu D, Chen X, Xu H.
    Cancer Lett; 2020 Dec 28; 495():22-32. PubMed ID: 32931884
    [Abstract] [Full Text] [Related]

  • 22. Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.
    Cao R, Liu M, Yin M, Liu Q, Wang Y, Huang N.
    J Chem Inf Model; 2012 Oct 22; 52(10):2730-40. PubMed ID: 22992059
    [Abstract] [Full Text] [Related]

  • 23. Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1.
    Akselsen OW, Odlo K, Cheng JJ, Maccari G, Botta M, Hansen TV.
    Bioorg Med Chem; 2012 Jan 01; 20(1):234-42. PubMed ID: 22137934
    [Abstract] [Full Text] [Related]

  • 24. Biological evaluation and molecular modelling study of podophyllotoxin derivatives as potent inhibitors of tubulin polymerization.
    Ma Y, Fang S, Li H, Han C, Lu Y, Zhao Y, Liu Y, Zhao C.
    Chem Biol Drug Des; 2013 Jul 01; 82(1):12-21. PubMed ID: 23786349
    [Abstract] [Full Text] [Related]

  • 25. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin.
    Lin CM, Ho HH, Pettit GR, Hamel E.
    Biochemistry; 1989 Aug 22; 28(17):6984-91. PubMed ID: 2819042
    [Abstract] [Full Text] [Related]

  • 26. Antimitotic and antitubulin activity of the tumor inhibitor steganacin.
    Wang RW, Rebhum LI, Kupchan SM.
    Cancer Res; 1977 Sep 22; 37(9):3071-9. PubMed ID: 560248
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Competitive mass spectrometry binding assay for characterization of three binding sites of tubulin.
    Li CM, Lu Y, Ahn S, Narayanan R, Miller DD, Dalton JT.
    J Mass Spectrom; 2010 Oct 22; 45(10):1160-6. PubMed ID: 20814887
    [Abstract] [Full Text] [Related]

  • 34. Conformationally restricted macrocyclic analogues of combretastatins.
    Mateo C, Alvarez R, Pérez-Melero C, Peláez R, Medarde M.
    Bioorg Med Chem Lett; 2007 Nov 15; 17(22):6316-20. PubMed ID: 17889536
    [Abstract] [Full Text] [Related]

  • 35. Combretastatin-based compounds with therapeutic characteristics: a patent review.
    Nainwal LM, Alam MM, Shaquiquzzaman M, Marella A, Kamal A.
    Expert Opin Ther Pat; 2019 Sep 15; 29(9):703-731. PubMed ID: 31369715
    [Abstract] [Full Text] [Related]

  • 36. -NH-dansyl isocolchicine exhibits a significantly improved tubulin-binding affinity and microtubule inhibition in comparison to isocolchicine by binding tubulin through its A and B rings.
    Das L, Datta AB, Gupta S, Poddar A, Sengupta S, Janik ME, Bhattacharyya B.
    Biochemistry; 2005 Mar 08; 44(9):3249-58. PubMed ID: 15736935
    [Abstract] [Full Text] [Related]

  • 37. Drugs that inhibit tubulin polymerization: the particular case of podophyllotoxin and analogues.
    Desbène S, Giorgi-Renault S.
    Curr Med Chem Anticancer Agents; 2002 Jan 08; 2(1):71-90. PubMed ID: 12678752
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Morpholino derivatives of benzyl-benzodioxole, a study of structural requirements for drug interactions at the colchicine/podophyllotoxin binding site of tubulin.
    Batra JK, Jurd L, Hamel E.
    Biochem Pharmacol; 1986 Nov 15; 35(22):4013-8. PubMed ID: 3778522
    [Abstract] [Full Text] [Related]

  • 40. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
    Naaz F, Haider MR, Shafi S, Yar MS.
    Eur J Med Chem; 2019 Jun 01; 171():310-331. PubMed ID: 30953881
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.